1-3 of 3
Anastasia Constantinidou
Close
Sort by
Journal Articles

A Phase I Study of GSK2816126, an Enhancer of Zeste Homolog 2(EZH2) Inhibitor, in Patients (pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Other Non-Hodgkin Lymphomas (NHL), Transformed Follicular Lymphoma (tFL), Solid Tumors and Multiple Myeloma (MM)

Timothy A. Yap, MD PhD, Jane N. Winter, MD, John P. Leonard, MD, Vincent Ribrag, MD, Anastasia Constantinidou, MD, Lisa Giulino-Roth, MD, Jean-Marie Michot, MD, Tariq A Khan, MD, Thierry Horner, PhD, Jennifer Carver, Teodora Pene Dumetrescu, PhD, Zangdong He, PhD, Michael T. McCabe, PhD, Caretha L. Creasy, PhD, Arindam Dhar, MBBS, MD PhD, Christopher Carpenter, MD PhD, Peter M Johnson, MA, MD
Journal: Blood
Blood (2016) 128 (22): 4203.
https://doi.org/10.1182/blood.V128.22.4203.4203
Published: 2016
Journal Articles

Successful Long-Term Outcomes in Patients with Lymphoma Achieving Only Partial Response on [ 18 f]FDG-PET Prior to Allogeneic Transplant

Robert N Lown, MBBS, MDRes), MRCP, FRCPath, Anastasia Constantinidou, Caroline Ebdon, Kabir Mohammed, Mark Ethell, MD, Ian Chau, MD, David Cunningham, FMedSci, Michael Potter, PhD, Bhupinder Sharma, MD
Journal: Blood
Blood (2014) 124 (21): 1249.
https://doi.org/10.1182/blood.V124.21.1249.1249
Published: 2014
Journal Articles

Residual Disease on FDG-PET and Multiple Lines of Prior Therapy Predict Poorer Outcomes Following Autologous Hematopoietic Stem Cell Transplantation for Lymphoma

Robert N Lown, MBBS, MDRes), MRCP, FRCPath, Anastasia Constantinidou, Caroline Ebdon, Kabir Mohammed, Mark Ethell, MD, Ian Chau, MD, David Cunningham, FMedSci, Michael Potter, PhD, Bhupinder Sharma, MD
Journal: Blood
Blood (2014) 124 (21): 3971.
https://doi.org/10.1182/blood.V124.21.3971.3971
Published: 2014